The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIb-SantPau, CIBERCV, Universitat Autónoma de Barcelona, Barcelona, Spain. Electronic address: https://twitter.com/j_alvarezgarcia.
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
J Am Coll Cardiol. 2020 Nov 17;76(20):2334-2348. doi: 10.1016/j.jacc.2020.09.549. Epub 2020 Oct 28.
Patients with pre-existing heart failure (HF) are likely at higher risk for adverse outcomes in coronavirus disease-2019 (COVID-19), but data on this population are sparse.
This study described the clinical profile and associated outcomes among patients with HF hospitalized with COVID-19.
This study conducted a retrospective analysis of 6,439 patients admitted for COVID-19 at 1 of 5 Mount Sinai Health System hospitals in New York City between February 27 and June 26, 2020. Clinical characteristics and outcomes (length of stay, need for intensive care unit, mechanical ventilation, and in-hospital mortality) were captured from electronic health records. For patients identified as having a history of HF by International Classification of Diseases-9th and/or 10th Revisions codes, manual chart abstraction informed etiology, functional class, and left ventricular ejection fraction (LVEF).
Mean age was 63.5 years, and 45% were women. Compared with patients without HF, those with previous HF experienced longer length of stay (8 days vs. 6 days; p < 0.001), increased risk of mechanical ventilation (22.8% vs. 11.9%; adjusted odds ratio: 3.64; 95% confidence interval: 2.56 to 5.16; p < 0.001), and mortality (40.0% vs. 24.9%; adjusted odds ratio: 1.88; 95% confidence interval: 1.27 to 2.78; p = 0.002). Outcomes among patients with HF were similar, regardless of LVEF or renin-angiotensin-aldosterone inhibitor use.
History of HF was associated with higher risk of mechanical ventilation and mortality among patients hospitalized for COVID-19, regardless of LVEF.
患有心力衰竭(HF)的患者在 2019 年冠状病毒病(COVID-19)中出现不良结局的风险可能更高,但针对该人群的数据很少。
本研究描述了在因 COVID-19 住院的 HF 患者中的临床特征和相关结局。
本研究对 2020 年 2 月 27 日至 6 月 26 日期间在纽约市 5 家西奈山卫生系统医院之一住院的 6439 例 COVID-19 患者进行了回顾性分析。从电子健康记录中获取临床特征和结局(住院时间、需要重症监护病房、机械通气和院内死亡率)。对于通过国际疾病分类第 9 版和/或第 10 版修订版代码识别为有 HF 病史的患者,通过手动图表提取来确定病因、功能分级和左心室射血分数(LVEF)。
平均年龄为 63.5 岁,45%为女性。与无 HF 的患者相比,有 HF 病史的患者住院时间更长(8 天 vs. 6 天;p < 0.001),机械通气风险更高(22.8% vs. 11.9%;调整后的优势比:3.64;95%置信区间:2.56 至 5.16;p < 0.001),死亡率更高(40.0% vs. 24.9%;调整后的优势比:1.88;95%置信区间:1.27 至 2.78;p = 0.002)。无论 LVEF 或肾素-血管紧张素-醛固酮抑制剂的使用情况如何,HF 患者的结局相似。
HF 病史与 COVID-19 住院患者机械通气和死亡率风险增加相关,而与 LVEF 无关。